usdaed

The FDA, an institution as ancient and inscrutable as the mountains themselves, has adjusted its timetable. The decision on orforglipron, initially slated for March, now drifts towards April, a delay of barely two weeks, yet enough to stir the anxieties of investors. It’s a minor postponement, they say, aligning with similar shifts for other pharmaceutical candidates. But in the world of biotechnology, where months can feel like lifetimes, and fortunes are built and undone on the basis of weeks, even a small delay can feel like an eternity. The air itself seems to thicken with uncertainty, like the prelude to a summer storm.

The reduction in Mr. Novack’s stake, whilst substantial in absolute terms, represents a mere 0.05% of the company’s outstanding shares as of January 24th, 2026. One might observe that such a disposition, whilst not inconsiderable, does not entirely dismantle his connection to Dynavax, leaving him with a position that, while diminished, still allows for a vested interest in its future prospects.

One seeks, naturally, to mitigate. To construct a bulwark against the coming…adjustment. The standard instruments – the broad indices – offer a comfort that feels increasingly illusory. Decades, they suggest, are required for recovery. A timescale that feels less like investment strategy and more like a sentence. One is left to wonder if the ‘recovery’ is merely a return to the starting point, a perpetual loop disguised as progress.

The week commenced with a flourish of patriotic expenditure, as USA Rare Earth secured a substantial injection of federal funding – $277 million, to be precise – and a further $1.3 billion in loans under the CHIPS Act, augmented by a generous $1.5 billion in private capital. A commendable display of faith, one might say, though whether it will actually result in anything beyond a proliferation of press releases remains to be seen. It does, however, offer a degree of de-risking, which is always appreciated by shareholders, and a bolstering of domestic supply, which is, of course, the official narrative.

The last twelve months haven’t been kind to either of them. Bitcoin took a hit, sure. But XRP? Down over forty percent. A steeper fall. The kind that makes a man check his assumptions, and his portfolio. It dipped below two dollars recently. A price point that felt less like support and more like a warning.

it’s more than double the recent median sell size for this particular insider. This isn’t a gradual trickle; it’s a noticeable adjustment. (One might compare it to rearranging deckchairs on the Titanic, except the Titanic is doing quite well, thank you, and the deckchairs are, in fact, highly sophisticated micro-acoustic microphones.)

Observe, if you will, the spectacle of the panicked herd. They believe, with a touching naiveté, that the market reflects reality. A most peculiar notion! The market, I assure you, is a stage upon which folly and greed perform a perpetual dance. To believe it a mirror to the world is to mistake a painted mask for a true face. Last June, the index plumbed even greater depths – a mere 50! One might have expected the very foundations of commerce to crumble. Instead, for a brief, deceptive moment, the sensible investor might have considered retreat. But alas, such prudence is rarely rewarded.

The principal advantage of this alteration lies in the potential relief from the constraints of Internal Revenue Code 280E. Currently, these businesses are denied the customary deductions afforded to other commercial ventures. A revision would allow them to account for essential expenses – salaries, rent, and the like – and, consequently, to demonstrate a more accurate reflection of their true profitability. A most welcome development, though one must consider whether such gains are already factored into current valuations.

They speak of an earnings report next week, February sixth. A chance for a reprieve, a flicker of hope. But hope, my friends, is a dangerous commodity. It sustains you only until the inevitable disappointment. The market, like a hungry beast, demands more than promises. It demands results. And Canopy Growth, for a long time, has offered little more than excuses.